CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05.
Data confirm strong anticancer activity of two lead compounds in CT-01 programResults support advancement of CT-01 compounds towards IND expected in late.